Physician profile
Eleanor Hebert Bourque
NPI 1215596531
$1,665.11
in general payments reported to CMS, 2019-2025
19 companies · $659 in 2025
The $659 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $90.69 · 2023: $172 · 2024: $635 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $430.29 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $167.33 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $130.96 | 2022-2025 | |
| Astellas Pharma US INC | $121.60 | 2024-2025 | Veozah |
| Lilly USA, LLC | $108.60 | 2021-2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $101.35 | 2024-2025 | |
| Novo Nordisk INC | $97.42 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $97.15 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $87.49 | 2023-2024 | Repatha, Otezla, Prolia |
| Medtronic, INC. | $81.70 | 2024-2025 | Minimed 780g |
| Pfizer INC. | $57.29 | 2024-2025 | |
| Edwards Lifesciences Corporation | $34.22 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $32.53 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $27.78 | 2025 | Gemtesa |
| Eisai INC. | $23.85 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $22.94 | 2024 | |
| Merck Sharp & Dohme LLC | $16.33 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.13 | 2024 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Bourque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.